Literature DB >> 28092671

PDE4D promotes FAK-mediated cell invasion in BRAF-mutated melanoma.

J Delyon1,2,3, A Servy1,2, F Laugier1,2, J André1,2, N Ortonne4, M Battistella5, S Mourah1,2,6, A Bensussan1,2, C Lebbé1,2,3, N Dumaz1,2.   

Abstract

The cyclic AMP (cAMP) signaling pathway is critical in melanocyte biology for regulating differentiation. It is downregulated by phosphodiesterase (PDE) enzymes, which degrade cAMP itself. In melanoma evidence suggests that inhibition of the cAMP pathway by PDE type 4 (PDE4) favors tumor progression. For example, in melanomas harboring RAS mutations, the overexpression of PDE4 is crucial for MAPK pathway activation and proliferation induced by oncogenic RAS. Here we showed that PDE4D is overexpressed in BRAF-mutated melanoma cell lines, constitutively disrupting the cAMP pathway activation. PDE4D promoted melanoma invasion by interacting with focal adhesion kinase (FAK) through the scaffolding protein RACK1. Inhibition of PDE4 activity or inhibition of PDE4D interaction with FAK reduced invasion. PDE4D expression is increased in patients with advanced melanoma and PDE4D-FAK interaction is detectable in situ in metastatic melanoma. Our study establishes the role of PDE4D in BRAF-mutated melanoma as regulator of cell invasion, and suggests its potential as a target for preventing metastatic dissemination.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28092671     DOI: 10.1038/onc.2016.469

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  38 in total

1.  Improved survival with MEK inhibition in BRAF-mutated melanoma.

Authors:  Keith T Flaherty; Caroline Robert; Peter Hersey; Paul Nathan; Claus Garbe; Mohammed Milhem; Lev V Demidov; Jessica C Hassel; Piotr Rutkowski; Peter Mohr; Reinhard Dummer; Uwe Trefzer; James M G Larkin; Jochen Utikal; Brigitte Dreno; Marta Nyakas; Mark R Middleton; Jürgen C Becker; Michelle Casey; Laurie J Sherman; Frank S Wu; Daniele Ouellet; Anne-Marie Martin; Kiran Patel; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2012-06-04       Impact factor: 91.245

2.  In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling.

Authors:  Nicolas Dumaz; Robert Hayward; Jan Martin; Lesley Ogilvie; Douglas Hedley; John A Curtin; Boris C Bastian; Caroline Springer; Richard Marais
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

3.  Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms.

Authors:  Nicolas Dumaz; Yvonne Light; Richard Marais
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

4.  MC1R and cAMP signaling inhibit cdc25B activity and delay cell cycle progression in melanoma cells.

Authors:  Jesse Lyons; Boris C Bastian; Frank McCormick
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-01       Impact factor: 11.205

5.  Phosphodiesterase-4 promotes proliferation and angiogenesis of lung cancer by crosstalk with HIF.

Authors:  S S Pullamsetti; G A Banat; A Schmall; M Szibor; D Pomagruk; J Hänze; E Kolosionek; J Wilhelm; T Braun; F Grimminger; W Seeger; R T Schermuly; R Savai
Journal:  Oncogene       Date:  2012-04-23       Impact factor: 9.867

6.  Focal adhesion kinase promotes the aggressive melanoma phenotype.

Authors:  Angela R Hess; Lynne-Marie Postovit; Naira V Margaryan; Elisabeth A Seftor; Galen B Schneider; Richard E B Seftor; Brian J Nickoloff; Mary J C Hendrix
Journal:  Cancer Res       Date:  2005-11-01       Impact factor: 12.701

7.  A complex between FAK, RACK1, and PDE4D5 controls spreading initiation and cancer cell polarity.

Authors:  Bryan Serrels; Emma Sandilands; Alan Serrels; George Baillie; Miles D Houslay; Valerie G Brunton; Marta Canel; Laura M Machesky; Kurt I Anderson; Margaret C Frame
Journal:  Curr Biol       Date:  2010-05-20       Impact factor: 10.834

Review 8.  Melanocyte biology and skin pigmentation.

Authors:  Jennifer Y Lin; David E Fisher
Journal:  Nature       Date:  2007-02-22       Impact factor: 49.962

9.  Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers.

Authors:  De-Chen Lin; Liang Xu; Ling-Wen Ding; Arjun Sharma; Li-Zhen Liu; Henry Yang; Patrick Tan; Jay Vadgama; Beth Y Karlan; Jenny Lester; Nicole Urban; Michèl Schummer; Ngan Doan; Jonathan W Said; Hongmao Sun; Martin Walsh; Craig J Thomas; Paresma Patel; Dong Yin; Daniel Chan; H Phillip Koeffler
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

10.  Identification of cells initiating human melanomas.

Authors:  Tobias Schatton; George F Murphy; Natasha Y Frank; Kazuhiro Yamaura; Ana Maria Waaga-Gasser; Martin Gasser; Qian Zhan; Stefan Jordan; Lyn M Duncan; Carsten Weishaupt; Robert C Fuhlbrigge; Thomas S Kupper; Mohamed H Sayegh; Markus H Frank
Journal:  Nature       Date:  2008-01-17       Impact factor: 49.962

View more
  10 in total

1.  Is Apremilast a Safe Option in Patients with History of Melanoma? A Case Series and a Review of the Literature.

Authors:  Alessio Gambardella; Gaetano Licata; Alina De Rosa; Giulia Calabrese; Roberto Alfano; Giuseppe Argenziano
Journal:  J Clin Aesthet Dermatol       Date:  2022-02

Review 2.  PDE4 subtypes in cancer.

Authors:  Samuel Hsien Lai; Guston Zervoudakis; Jesse Chou; Mark E Gurney; Kelly M Quesnelle
Journal:  Oncogene       Date:  2020-03-20       Impact factor: 9.867

Review 3.  Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.

Authors:  George S Baillie; Gonzalo S Tejeda; Michy P Kelly
Journal:  Nat Rev Drug Discov       Date:  2019-08-06       Impact factor: 84.694

4.  Inhibition of PDE4 by apremilast attenuates skin fibrosis through directly suppressing activation of M1 and T cells.

Authors:  Qiu-Kai Lu; Chen Fan; Cai-Gui Xiang; Bing Wu; Hui-Min Lu; Chun-Lan Feng; Xiao-Qian Yang; Heng Li; Wei Tang
Journal:  Acta Pharmacol Sin       Date:  2021-04-13       Impact factor: 7.169

Review 5.  Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions.

Authors:  Antoine Mousson; Emilie Sick; Philippe Carl; Denis Dujardin; Jan De Mey; Philippe Rondé
Journal:  Cancers (Basel)       Date:  2018-08-21       Impact factor: 6.639

6.  Cancer Stem Cells: Emergent Nature of Tumor Emergency.

Authors:  Yaroslav R Efremov; Anastasia S Proskurina; Ekaterina A Potter; Evgenia V Dolgova; Oksana V Efremova; Oleg S Taranov; Aleksandr A Ostanin; Elena R Chernykh; Nikolay A Kolchanov; Sergey S Bogachev
Journal:  Front Genet       Date:  2018-11-16       Impact factor: 4.599

7.  High expression of PDE4D correlates with poor prognosis and clinical progression in pancreaticductal adenocarcinoma.

Authors:  Fude Liu; Jieyi Ma; Kebing Wang; Zhi Li; Qingping Jiang; Hui Chen; Wen Li; Jintang Xia
Journal:  J Cancer       Date:  2019-10-17       Impact factor: 4.207

Review 8.  Targeting GPCRs and Their Signaling as a Therapeutic Option in Melanoma.

Authors:  Jérémy H Raymond; Zackie Aktary; Lionel Larue; Véronique Delmas
Journal:  Cancers (Basel)       Date:  2022-01-29       Impact factor: 6.639

9.  Whole-genome screen identifies diverse pathways that negatively regulate ciliogenesis.

Authors:  Marion Failler; Ariadna Giro-Perafita; Mikito Owa; Shalini Srivastava; Chi Yun; David J Kahler; Derya Unutmaz; Francisco J Esteva; Irma Sánchez; Brian D Dynlacht
Journal:  Mol Biol Cell       Date:  2020-11-18       Impact factor: 4.138

10.  Phosphodiesterase 4D Depletion/Inhibition Exerts Anti-Oncogenic Properties in Hepatocellular Carcinoma.

Authors:  Federica Ragusa; Nadia Panera; Silvia Cardarelli; Marco Scarsella; Marzia Bianchi; Stefano Biagioni; Mauro Giorgi; Anna Alisi; Mara Massimi
Journal:  Cancers (Basel)       Date:  2021-05-01       Impact factor: 6.639

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.